{"id":"W2768323313","doi":"10.1093/annonc/mdx666.003","title":"Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Adverse effect; Placebo; Clinical endpoint; Hepatocellular carcinoma; Oncology; Surgery; Randomized controlled trial; Clinical trial; Phases of clinical research; Cancer; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001449849,0.001546335,0.002512425,0.0003613759,0.0004512781,0.0014461,0.0009916221,0.001396491,0.009264402],"category_scores_gemma":[0.001174163,0.0008120984,0.001654387,0.0003402313,0.001207848,0.001353074,0.0004002742,0.004128769,0.001872924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001026338,"about_ca_system_score_gemma":0.001283893,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001137175,"about_ca_topic_score_gemma":0.00225061,"domain_scores_codex":[0.9996516,0.0001522187,0.00001351986,0.00007486885,0.0000271321,0.00008068263],"domain_scores_gemma":[0.9993529,0.0001692909,0.0001076232,0.00006772368,0.00003267388,0.0002698404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9655833,0.009446818,0.0004821814,0.0004336346,0.0008724793,0.00003735443,0.00006141331,0.0006485342,0.004023879,0.0001828124,0.001651681,0.01657588],"study_design_scores_gemma":[0.9484358,0.04829046,0.001062987,0.00001687687,0.0003033588,0.00003784732,0.00002216707,0.000444334,0.0004921433,0.0002271222,0.0006534078,0.00001340683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987094,0.002830641,0.0008157348,0.0007778509,0.0005460327,0.002568011,0.001649638,0.0002354977,0.003482677],"genre_scores_gemma":[0.9848621,0.001866858,0.001684973,0.001611551,0.000371535,0.002813795,0.001763794,0.00006077716,0.00496461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009264402,"threshold_uncertainty_score":0.03099251,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2099275869011265,"score_gpt":0.4216010728658582,"score_spread":0.2116734859647317,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}